A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors
Mechanism of Action
ASP1002 is anti-CLDN4 and anti-CD137 bispecific antibody
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from ASP1002
- How the study agent is acting on your body
Location
Similar Trials
Yes
No
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.